Patient ID	Patient Name		Birth Date	Sex	Age
SA00178897	TESTINGRNV, REPORTS NORM		1979-05-30	F	46
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00178897	SA00178897	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		15 Jan 2026 08:00			

Interference Eval, Heterophile, HCG

HCG, Interference Interpretation

Result Name	Value	Unit	Reference Value	Performing Site
HCG, Interference Heterophile	Not Detected			SDL

HCG, Interpretation SDL

The specimen was evaluated for potential heterophile antibody interference in the Roche Elecsys total beta-HCG (HCG) immunoassay. Evaluation consisted of pretreatment with commercial heterophile antibody blocking reagents, serial dilution of the sample, and testing on an alternate platform (Beckman Coulter). The presence of heterophile antibody interference in the Roche Elecsys assay is not suspected when the results from the pretreatment, serial dilutions and the alternative platform agree within 20% of the original result.

This heterophile antibody interference evaluation does not rule out the presence of other types of interfering substances such as biotin. There may be some samples with extremely strong heterophilic interference. In such cases heterophile blocking reagents may not be able to block all of the assay interference.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592

MAYO CLINIC LABORATORIES

Patient ID	Patient Name		Birth Date	Sex	Age
SA00178897	TESTINGRNV, REPORTS NORM		1979-05-30	F	46
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00178897	SA00178897	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		15 Jan 2026 08:00			

Result Name	Value	Unit	Reference Value	Performing Site
Beta-HCG, Quantitative, S	5.0	IU/L		1 SDL

HCG concentrations above the reference interval can occur if the patient is hypogonadal. Inadequate negative feedback to the pituitary, due to low sex hormone levels, may result in elevated HCG. It is recommended that serum luteinizing hormone (LH) or follicle stimulating hormone (FSH) be determined to assess this possibility.

REFERENCE VALUE

Females:
<1.0 (Premenopausal, non-pregnant)
<7.0 (Postmenopausal)

The testing method is an electrochemiluminescence assay manufactured by Roche Diagnostics Inc. and performed on the Modular or Cobas system.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Test results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Human chorionic gonadotropin (hCG) values are not interpretable in pregnant females for the investigation of malignant disease.

HCG, Alternative Method, S	5.0	IU/L	<6.2	1 SDL

The testing method is an immunoenzymatic assay manufactured by Beckman Coulter Inc. and performed on the UniCel DxI 800.

Values obtained with different assay methods or kits may be different and cannot be used interchangeably.

Test results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Human chorionic gonadotropin (hCG) values are not interpretable in pregnant females for the investigation of malignant disease.

Received: 16 Jan 2026 12:09 **Reported:** 16 Jan 2026 12:10

Laboratory Notes

1 This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592